Avastin and Herceptin sales fuel Genentech income rise

Share this article:
Genentech reported a third-quarter net income that rose 56 percent aided by sales of its colon cancer drug Avastin (bevacizumab) and breast cancer drug Herceptin (trastuzumab).
 Avastin sales rose 78 percent to $325.2 million. Sales of breast cancer drug Herceptin rose 70 percent to $215 million.
Although sales of Avastin leveled off for its FDA-approved indication, colon cancer, doctors are starting to use it off-label for breast and lung cancer. Off-label prescribing has also boosted sales of Herceptin. The drug is approved for the treatment of metastatic breast cancer in certain women, however doctors are trying it in earlier stages of the disease.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...